Skip to content
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Clinical Topics
View All
Depression
Neurologic
Anxiety
Schizophrenia
Trauma
Psychopharmacology
Bipolar
Tardive Dyskinesia
OCD
Addiction
View All
Columns
View All
ASCP Corner
Clinical & Practical Psychopharmacology
Rounds General Hospital
Academic Highlights
Banner Alzheimer’s Institute
Focus on Geriatric Psychiatry
Roland Jimenez, BA
JCP
Original Research
Long-Term Valbenazine for Tardive Dyskinesia
November 14, 2017
Valbenazine, a VMAT2 inhibitor, is approved for the treatment of tardive dyskinesia. However, its long-term safety and efficacy have not been reported. This extension of the KINECT 3 study...
Stewart A. Factor
,
Gary Remington
,
Cynthia L. Comella
, et al